171 related articles for article (PubMed ID: 35020817)
1. Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes.
Shao H; Li P; Guo J; Fonseca V; Shi L; Zhang P
Diabetes Care; 2022 Feb; 45(2):e32-e33. PubMed ID: 35020817
[No Abstract] [Full Text] [Related]
2. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
Packer M
Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
[No Abstract] [Full Text] [Related]
3. GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection.
Aroda VR; Billings LK
J Am Coll Cardiol; 2023 Aug; 82(6):526-528. PubMed ID: 37532423
[No Abstract] [Full Text] [Related]
4. Contemporary utilization of GLP1 receptor agonists and SGLT2 inhibitors in patients with diagnosed type 2 diabetes and cardiovascular disease in the United States.
Al-Kindi SG; Janus SE; Neeland IJ; Rajagopalan S
J Diabetes Complications; 2022 Jul; 36(7):108224. PubMed ID: 35667964
[No Abstract] [Full Text] [Related]
5. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
[No Abstract] [Full Text] [Related]
6. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
[TBL] [Abstract][Full Text] [Related]
7. For Patients with Type 2 Diabetes Mellitus Who Are Taking a GLP-1 Receptor Agonist, an SGLT2 Inhibitor May Be Preferred to a Sulfonylurea as Add-on Therapy.
Ebell MH
Am Fam Physician; 2021 Oct; 104(4):424. PubMed ID: 34652104
[No Abstract] [Full Text] [Related]
8. Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.
Hocher B; Tsuprykov O
Nat Rev Nephrol; 2017 Dec; 13(12):728-730. PubMed ID: 28989173
[No Abstract] [Full Text] [Related]
9. SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Shaughnessy AF
Am Fam Physician; 2021 Aug; 104(2):206. PubMed ID: 34383432
[No Abstract] [Full Text] [Related]
10. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
Lee MMY; Petrie MC; McMurray JJV; Sattar N
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
[TBL] [Abstract][Full Text] [Related]
11. Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis.
Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)
Lancet Diabetes Endocrinol; 2021 Dec; 9(12):825-836. PubMed ID: 34656210
[TBL] [Abstract][Full Text] [Related]
12. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
[TBL] [Abstract][Full Text] [Related]
13. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
[TBL] [Abstract][Full Text] [Related]
14. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.
Bailey CJ
Lancet Diabetes Endocrinol; 2020 Feb; 8(2):97-99. PubMed ID: 31843565
[No Abstract] [Full Text] [Related]
15. Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.
Anderson S; Cotiguala L; Tischer S; Park JM; McMurry K
Ann Pharmacother; 2021 Apr; 55(4):496-508. PubMed ID: 32795145
[TBL] [Abstract][Full Text] [Related]
16. The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study.
Morton JI; Ilomӓki J; Magliano DJ; Shaw JE
Diabetologia; 2021 Feb; 64(2):349-360. PubMed ID: 33078206
[TBL] [Abstract][Full Text] [Related]
17. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
Dougherty JA; Guirguis E; Thornby KA
Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
[TBL] [Abstract][Full Text] [Related]
19. Impact of CVOTs in primary and secondary prevention of kidney disease.
De Cosmo S; Viazzi F; Piscitelli P; Leoncini G; Mirijello A; Bonino B; Pontremoli R
Diabetes Res Clin Pract; 2019 Nov; 157():107907. PubMed ID: 31676332
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
Lim S; Kim KM; Nauck MA
Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
